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WeOBJECTIVES This study classiﬁed and quantiﬁed the variation in fractional ﬂow reserve (FFR) due to ﬂuctuations in
systemic and coronary hemodynamics during intravenous adenosine infusion.
BACKGROUND Although FFR has become a key invasive tool to guide treatment, questions remain regarding its
repeatability and stability during intravenous adenosine infusion because of systemic effects that can alter driving
pressure and heart rate.
METHODS We reanalyzed data from the VERIFY (VERiﬁcation of Instantaneous Wave-Free Ratio and Fractional Flow
Reserve for the Assessment of Coronary Artery Stenosis Severity in EverydaY Practice) study, which enrolled consecutive
patients who were infused with intravenous adenosine at 140 mg/kg/min and measured FFR twice. Raw phasic pressure
tracings from the aorta (Pa) and distal coronary artery (Pd) were transformed into moving averages of Pd/Pa. Visual
analysis grouped Pd/Pa curves into patterns of similar response. Quantitative analysis of the Pd/Pa curves identiﬁed the
“smart minimum” FFR using a novel algorithm, which was compared with human core laboratory analysis.
RESULTS A total of 190 complete pairs came from 206 patients after exclusions. Visual analysis revealed 3 Pd/Pa
patterns: “classic” (sigmoid) in 57%, “humped” (sigmoid with superimposed bumps of varying height) in 39%, and
“unusual” (no pattern) in 4%. The Pd/Pa pattern repeated itself in 67% of patient pairs. Despite variability of Pd/Pa
during the hyperemic period, the “smart minimum” FFR demonstrated excellent repeatability (bias 0.001, SD 0.018,
paired p ¼ 0.93, r2 ¼ 98.2%, coefﬁcient of variation ¼ 2.5%). Our algorithm produced FFR values not signiﬁcantly
different from human core laboratory analysis (paired p ¼ 0.43 vs. VERIFY; p ¼ 0.34 vs. RESOLVE).
CONCLUSIONS Intravenous adenosine produced 3 general patterns of Pd/Pa response, with associated variability in
aortic and coronary pressure and heart rate during the hyperemic period. Nevertheless, FFR – when chosen appropri-
ately – proved to be a highly reproducible value. Therefore, operators can conﬁdently select the “smart minimum” FFR for
patient care. Our results suggest that this selection process can be automated, yet comparable to human core laboratory
analysis. (J Am Coll Cardiol Intv 2015;8:1018–27) © 2015 by the American College of Cardiology Foundation.m the *Weatherhead PET Center For Preventing and Reversing Atherosclerosis, Division of Cardiology, Department of Med-
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AB BR E V I A T I O N S
AND ACRONYM S
FFR = fractional ﬂow reserve
IV = intravenous
Pa = aortic pressure
PCI = percutaneous coronary
intervention
Pd = distal coronary pressure
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1019D uring the past 20 years, fractional ﬂowreserve (FFR) has evolved from its ﬁrst an-imal model and theoretical introduction
(1) to an everyday clinical tool to guide coronary
revascularization. As a result of 3 major randomized
controlled trials (2–4) and a host of observational
studies (5), both European (6) and American (7) guide-
lines recommend FFR when making treatment deci-
sions for intermediate coronary lesions that lack
deﬁnitive proof of ischemia, although the key
randomized trials utilized FFR in lesions of at least
50% diameter stenosis, both intermediate and severe.SEE PAGE 1028A cornerstone of FFR since its inception has been
the use of hyperemia. Because of autoregulation (8),
only during hyperemia does a pressure ratio indicate
the relative reduction in peak myocardial ﬂow caused
by a stenosis. Although the ﬁrst FFR paper (1) used
papaverine, the introduction of intravenous (IV)
adenosine (9) allowed for sustained hyperemia with a
superior safety proﬁle, given the shorter duration and
small risk of torsade de pointes with papaverine.
The FAME trial used only IV adenosine (3) due to its
reliability and ease of use. An opinion document on
FFR for clinical trials speciﬁcally recommended
IV adenosine over alternative agents such as intra-
coronary adenosine, papaverine, and nitroprusside
(10).
However, some investigators have recently ques-
tioned the validity of FFR measurements made dur-
ing IV adenosine infusion (11,12). Speciﬁcally, some
investigators proposed that only the FFR measured
during “stable hyperemia” should be used to guide
treatment, even if lower values had been observed
(11). Other investigators noted common FFR insta-
bility during IV adenosine infusion, but still recom-
mended always using the lowest observed value (12).from St. Jude Medical (for NCT02184117) and Volcano Corporation (for NCT0
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tracings from the VERIFY (VERiﬁcation of
Instantaneous Wave-Free Ratio and Frac-
tional Flow Reserve for the Assessment of
Coronary Artery Stenosis Severity in
EverydaY Practice) study (13) to answer 4
speciﬁc questions. First, what patterns of
response occur during IV adenosine infusion?
Second, how stable are aortic pressure (Pa),
distal coronary pressure (Pd), heart rate, and FFR
during the hyperemic period? Third, given these
patterns of response and variable stability, can oper-
ators make repeatable FFR measurements? Fourth,
can FFR selection be automated with comparable
agreement to human choices from a physiology core
laboratory?
METHODS
The VERIFY study has already been published (13).
We sought no further ethics board review for the
current analysis, because each patient provided
written informed consent for VERIFY, and the pres-
sure tracings and clinical variables contained no
conﬁdential identiﬁers.
DATA COLLECTION. In brief, the VERIFY study
enrolled consecutive patients referred to 5 interna-
tional centers for FFR-guided angiography or per-
cutaneous coronary intervention (PCI). After its
identiﬁcation by the operator as a potential PCI
target, 1 lesion/patient underwent standard FFR
measurement using IV adenosine infusion at a dose of
140 mg/kg/min via a central or large antecubital vein,
starting approximately 10 cardiac cycles into the
recording. Pressure recordings started 2 min after the
last contrast injection and continued for 2 min unless
the patient did not tolerate the infusion. FFR mea-
surement was then repeated after a 2-min rest period.2328820), makers of intracoronary pressure and ﬂow
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1020A handful of subjects had only 1 successful recording
saved, and a few tracings were excluded due to loss of
the Pd or Pa signal during the recording. We included
only subjects with 2 valid, paired tracings to allow for
repeatability analysis and comparison.
Operators used a coronary pressure wire and
recording system (Certus and RadiAnalyzer Xpress, St.
JudeMedical, St. Paul,Minnesota), storing anonymous
tracings centrally for study analysis. Every 10 ms the
recording system sampled aortic and coronary pres-
sure to 0.1 mm Hg. Additionally, it provided a moving
average for the pressure ratio of Pd/Pa at each sample
point, computed as a retrospective average of uniform
weight, of varying length depending on the heart rate,
and without any error checking of the underlying
pressure data (J. Svanerud, St. Jude Medical, personal
communication, July 2014). This moving average
served as an automated FFR selection to be conﬁrmed
or adjusted by the human operator.
“SMART MINIMUM” FFR ALGORITHM. Our algorithm
ﬁrst identiﬁed anacrotic limbs in the aortic pressure
tracing to deﬁne the bounds of each cardiac cycle.
The identiﬁcation used high- and low-frequency
ﬁltering and a second derivative to select local
minima followed by sharp upswings. To avoid well-
known, high-frequency edge effects from a sharp,
step-function average (“boxcar”), we instead used a
Gaussian-weighted average of 1 s width. To align the
phase of the weighted average with the underlying
data, we centered a complete Gaussian at each sample
point instead of using a retrospective average, which
would lag the instantaneous change.
Each cardiac cycle then underwent quality control
checks for both Pa and Pd to ensure physiologically
plausible values for systolic and diastolic pressures,
pulse pressure, and beat duration (see Online
Appendix for further details). For those cardiac cycles
of sufﬁcient quality, the Gaussian-weighted average at
midbeat summarized the Pa, Pd, and Pd/Pa, whereas
the overall duration deﬁned the heart rate.
The “smart minimum” FFR was selected as the
lowest average of 5 consecutive cardiac cycles of
sufﬁcient quality within a run of 9 consecutive qual-
ity beats. The term “smart minimum” distinguishes
its selection from a “simple minimum” that does not
impose quality checks on the underlying pressure
data. Automatic selection of rest Pd/Pa chose the
highest average of 5 consecutive cardiac cycles of
sufﬁcient quality that occurred before the smart
minimum FFR.
To compare our algorithm against other plausible
FFR selections, we recorded the simple minimum
FFR as the lowest average Pd/Pa value provided bythe pressure recording system. We recorded the
Pd/Pa value 1 and 2 min after the start of the tracing to
mimic recommendations to wait a ﬁxed period of
time before measuring FFR. We also tried excluding
15 s after the transition to and start of hyperemia to
investigate recommendations to avoid FFR measure-
ments during adenosine onset. Finally, to study the
sensitivity of our algorithm to the width of the
Gaussian-weighted average, number of consecutive
beats for selection, and type of moving average
(Gaussian or boxcar), we varied these parameters.
MANUAL PARSING AND CLASSIFICATION OF Pd/Pa
TRACINGS. After applying the “smart minimum” al-
gorithm, we manually parsed each tracing into
sequential components: rest period, transition to hy-
peremia, hyperemic period, and pullback during hy-
peremia or a ﬁnal transition back to rest. Not all periods
were present in every tracing. We excluded periods of
the tracing with invalid data due to loss of Pa and/or Pd
of sufﬁcient quality. Note that the “smart minimum”
algorithm did not use the manual parsing, which was
only used for subsequent display and analysis.
On the basis of these components, we computed
the percentage of the hyperemic period above 0.02 of
the smart minimum FFR, because 0.02 represents
approximately 1 SD of the difference between re-
peated measurements (13). We also computed the
25th, 50th (median), and 75th percentiles of Pa, Pd,
Pd/Pa, and heart rate during the hyperemic period to
quantify variability. We recorded the mean Pd/Pa
during the entire hyperemic period.
Three authors (N.P.J., R.L.K., and K.L.G.) inde-
pendently grouped the Pd/Pa responses into patterns,
blinded to the enrolling center and paired tracing for
each subject. Disagreements were resolved by
consensus discussion. To facilitate visual analysis
and comparison of Pd/Pa responses, we used spark-
lines: “data-intense, design-simple, word-sized
graphics” (14).
HUMAN CORE LABORATORY ANALYSIS. As part of
previous and separate publications, each tracing had
already been analyzed centrally and independently
at 2 different core laboratories as detailed in the
Online Appendix. Each human analysis provided
Pd/Pa and FFR values for accepted tracings, serving
as reference standards for the “smart minimum”
algorithm described in the previous text.
STATISTICAL METHODS. Statistical analyses were
performed in R version 3.1.0 (R Foundation for
Statistical Computing, Vienna, Austria). Applicable
tests were 2-tailed, and p < 0.05 was considered sta-
tistically signiﬁcant. We used standard summary
TABLE 1 Summary of FFR Algorithm Comparisons and Test/Retest Repeatability
Comparison
FFR
CommentsBias SD p Value*
FFR Algorithms Proposed by Others Compared With Smart Minimum Algorithm
vs. simple minimum† 0.046 0.128 <0.001 Simple minimum
overestimates severity
vs. hyperemic mean 0.022 0.020 0.008 Mean underestimates
severity
vs. 1-min wait 0.065 0.077 <0.001 1-min wait overestimates
severity
vs. 2-min wait 0.061 0.077 <0.001 2-min wait overestimates
severity
vs. exclude 15 s after transition
to hyperemia
0.002 0.008 0.88 No improvement from
waiting after
onset of hyperemiavs. exclude 15 s after start
of hyperemia
0.010 0.031 0.30
Human Core Laboratory Comparisons With Smart Minimum Algorithm
VERIFY vs. RESOLVE 0.019 0.013 0.13 No signiﬁcant difference
among smart minimum
algorithm and human core
laboratory selections
Smart minimum vs. RESOLVE 0.012 0.010 0.34
Smart minimum vs. VERIFY 0.006 0.007 0.43
Test/Retest Repeatability
VERIFY human core laboratory <0.001 0.019 0.98 “Smart minimum” algorithm
performs as well as
human core laboratory
“Smart minimum” algorithm 0.001 0.018 0.93
Technical Components of Smart Minimum Algorithm
vs. 1 beat 0.003 0.008 0.74 No signiﬁcant difference
among various technical
components in smart
minimum algorithm
vs. 3 beats 0.001 0.003 0.88
vs. 7 beats 0.001 0.002 0.88
vs. 9 beats 0.002 0.003 0.77
vs. Gaussian 0.5-s width <0.001 0.001 0.95
vs. Gaussian 2-s width 0.001 0.002 0.93
vs. 5-beat boxcar 0.002 0.018 0.90
*p value from paired test. †Minimal Pd/Pa for entire tracing without error checking provided by the pressure
recording system software (see Methods section).
FFR ¼ fractional ﬂow reserve; Pa ¼ aortic pressure; Pd ¼ distal coronary pressure; VERIFY ¼ VERiﬁcation of
Instantaneous Wave-Free Ratio and Fractional Flow Reserve for the Assessment of Coronary Artery Stenosis
Severity in EverydaY Practice.
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1021statistical tests as detailed in the Online Appendix. All
physiological data in this paper comes from our
“smart minimum” algorithm except for a few human
core laboratory and pressure recording system results
that we explicitly identify as such in the text and in
Table 1.
RESULTS
The VERIFY study enrolled 206 patients (13). Already
8 patients had only 1 tracing, and we excluded
another 8 patients because of insufﬁcient data in at
least 1 tracing, leaving 190 patients with complete
pairs. Figure 1 depicts a sample tracing and its anal-
ysis, showing raw phasic pressure data, beat sum-
maries, and the selected “smart minimum” FFR value
with its associated pressures and heart rate during the
hyperemic period. Online Figure F1 displays all Pd/Pa
tracings (including excluded tracings), marking both
the smart minimum FFR and rest Pd/Pa visually.
Further results can be found in the Online Appendix.
PATTERNS OF PD/PA RESPONSE. Visual analysis of
the Pd/Pa tracings revealed 3 major patterns of
response as summarized in Figure 2: “classic” (sig-
moid) in 215 of 380 (57%), “humped” (sigmoid with
superimposed bumps of varying height) in 151 (40%),
and “unusual” (no pattern) in 14 (4%). Online
Figures F2 (“classic”), F3 (“humped”), and F4 (“un-
usual”) all display Pd/Pa tracings as categorized into
these 3 groups.
The pattern of Pd/Pa response remained un-
changed in the majority of pairs, as summarized in
Figure 3. Speciﬁcally, in 77 pairs (41% of 190) both
responses were classic, in 46 pairs (24%) both re-
sponses were humped, and in 5 pairs (3%) both
responses were unusual. Only in 33% of pairs
did the response pattern differ: 37 pairs (20%)
were ﬁrst humped then classic, 21 pairs (11%) were
ﬁrst classic then humped, and 4 pairs (2%) were
unusual once.
Online Table T1 summarizes the clinical charac-
teristics for all pairs, as well as each response pattern.
With the exception of the coronary vessel, no clinical
or physiological characteristic differed signiﬁcantly
among the response patterns. Online Figures F5 to
F10 and Table T2 detail the lack of repeatable hemo-
dynamic responses to IV adenosine.
REPEATABILITY OF FFR DESPITE FLUCTUATING
HEMODYNAMICS. Figures 4 and 5 demonstrate that
paired measurements of FFR remain highly re-
peatable, with an extremely linear relationship
(r2 ¼ 98.2%, implying that the baseline FFR mea-
surement explains over 98% of the populationvariation in the repeated FFR measurement), insig-
niﬁcant bias (D ¼ 0.001, paired p ¼ 0.93), and a small
SD (0.018) especially compared with the mean (coef-
ﬁcient of variation 2.5%). By contrast, aortic pressure,
distal coronary pressure, and heart rate at the time of
FFR ﬂuctuated greatly between paired measure-
ments, with smaller correlation coefﬁcients and
larger SD compared with the mean, as detailed further
in the Online Appendix.
Among Pd/Pa patterns, Bland-Altman analysis of
paired FFR measurements revealed similar ﬁndings to
the whole group but worse for the small minority with
unusual responses: bias 0.001 and SD 0.017 when
both were classic, bias 0.005 and SD 0.017 when both
were humped, bias 0.002 and SD 0.019 when one
was classic and the other was humped, and bias 0.001
and SD 0.024 when 1 or both were unusual.
FIGURE 1 Example Raw Tracing With Analysis
(Left) Phasic aortic pressure (Pa) (red) and distal coronary pressure (Pd) (blue) tracings. An intravenous infusion of adenosine at 140 mg/kg/min
began after approximately 10 cardiac cycles and continued for the duration of the recording. (Right)Analysis of the phasic data shows the average
Pa (red) and Pd (blue) pressures for each cardiac cycle, as well as derived heart rate (green) and Pd/Pa (black). Vertical dashed gray lines denote
the hyperemic period.Horizontal barsmark the smart minimum fractional ﬂow reserve (FFR) and its associated pressures and heart rate. Note the
stability of Pd/Pa during the hyperemic period (coefﬁcient of dispersion [COD] 1.5%) compared with the much wider variations in aortic pressure
(COD 7.6%), coronary pressure (COD 7.5%), and heart rate (COD 7.2%). Also, ﬁne oscillations in the pressure tracings arise from the interplay of
several peripheral and coronary control mechanisms as studied in animal models and addressed in the Online Appendix. bpm ¼ beats/min.
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1022NECESSARY DURATION OF IV ADENOSINE INFUSION.
Figure 6 displays the cumulative distribution of
the observed times from starting the baseline
recording until reaching the smart minimum FFR. The
population response to IV adenosine infusion dis-
played a sigmoid shape, with a sharp rise between
about 50 and 100 s, indicating that 75% of patients
achieved a minimum FFR value before or during this
window.
ALGORITHM COMPARISONS. Table 1 summarizes the
performance of the “smart minimum” FFR algorithm,
with further details in Online Table T3. Its ﬁrst sec-
tion explored other potential algorithms for selecting
FFR. Choosing the simple minimum without error
checking or waiting 1 or 2 min overestimated lesion
severity. Taking the mean FFR during the entire hy-
peremic period underestimated lesion severity.
Excluding 15 s after the onset of hyperemia did not
alter the results.
In the second section of Table 1, no signiﬁcant
difference existed when comparing our algorithm to
existing results from previous publications by the
VERIFY (13) and RESOLVE (15) core laboratories,
especially considering the variation between the 2
core laboratories. In its third section, Table 1 quan-
tiﬁes the observation that our algorithm performed aswell as the VERIFY core laboratory in terms of bias
and SD during repeat measurements. The ﬁnal sec-
tion evaluated various technical components of the
“smart minimum” algorithm. No signiﬁcant differ-
ences were found for number of selected beats,
Gaussian width, or a boxcar average.DISCUSSION
Our reanalysis of the VERIFY tracings answered 4
important questions regarding the use of IV adeno-
sine to measure FFR. First, 3 general patterns of Pd/
Pa response were seen during IV adenosine infusion,
as summarized in Figures 2 and 3, with numerous
speciﬁc examples detailed in Online Figures F1
to F4. Although an approximate 60% majority of
tracings displayed a “classic” (sigmoid) response
with a stable shelf, a substantial 40% minority did
not. Therefore, operators must be prepared to
observe ﬂuctuations in Pd/Pa that never settle into
a ﬂat response despite a constant infusion of IV
adenosine.
Second, during the hyperemic period, substantial
changes occurred in the absolute aortic and coronary
pressures and heart rate, with much smaller changes
in the Pd/Pa ratio. Nevertheless, to answer the
FIGURE 2 Patterns of Pd/Pa During Hyperemia
Three major Pd/Pa response patterns of varying frequency occurred during steady intra-
venous adenosine infusion: “classic” (sigmoid), “humped” (sigmoid with superimposed
bumps of varying height), and “unusual” (no pattern). For each observed example, the red
dot marks the smart minimum FFR. The blue scale for Pd/Pa and time applies to the
example tracings. Abbreviations as in Figure 1.
FIGURE 3 Paired Patterns of Pd/Pa During Hyperemia
Each lesion underwent repeat study separated by 2 min of rest, producing 5 observed
paired patterns of varying frequency. For each observed example, the red dot marks the
smart minimum FFR. The blue scale for Pd/Pa and time applies to the example tracings.
Abbreviations as in Figure 1.
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1023third question, the minimum FFR remains a highly
repeatable measurement. Indeed, our Figure 4 can be
seen as the “natural history” version of previous work
that speciﬁcally manipulated systemic pressure,
heart rate, and contractility yet demonstrated that
FFR remained insensitive to these parameters (16).
Therefore, these ﬁndings together suggest that the
primary focus during FFR measurement should
remain on Pd/Pa, not its speciﬁc components or the
associated heart rate. Although profound systemic
hypotension during vasodilation can drop absolute
coronary ﬂow, thereby reducing the pressure loss and
increasing the Pd/Pa value, such extremes occur
infrequently and, in our experience, respond to a
ﬂuid challenge. As we have summarized previously
(17), FFR stands apart among commonly used diag-
nostic tests in cardiology for being highly repeatable.
Fourth, our “smart minimum” algorithm demon-
strated no signiﬁcant differences from human choices
made in a physiology core laboratory. As with every
diagnostic test, the physician must understand its
physiologic importance, measurement details in-
cluding pitfalls, and clinical interpretation. However,
many if not all tests beneﬁt from automation, stan-
dardization, and transparency. If the FFR recording
equipment could reliably and quickly select the cor-
rect FFR value in a vast majority of cases, then this
improvement could facilitate and optimize decision
making in clinical practice. Furthermore, a common,
transparent algorithm among manufacturers of FFR
recording devices would facilitate portability and
comparability.
How can pressure wire recording systems help the
operator separate the collection of massive elements
of data (during which the operator must focus on
avoiding pitfalls such as damping, whip, and signal
loss) from their visualization and interpretation (dur-
ing which the operator must focus on global pattern
recognition and FFR selection)? Our work suggests
that sparklines of Pd/Pa, as in our ﬁgures (14), could
offer a superior method for visualizing intracoronary
pressure measurements in the catheterization labo-
ratory, medical record, and published scientiﬁc data.
For example, the second tracing in Figure 2 summa-
rizes 14,285 data points collected over a 2.4-min
period, but uses a visual area only 3 cm wide and
1 cm high although clearly marking the FFR value and
revealing a classic (sigmoid) response pattern.
Our ﬁndings should not be misinterpreted as a
radical change in how FFR should be analyzed. Rather,
the “smart minimum” algorithm codiﬁes the clinical
practice of expert users, as exempliﬁed by the lack
of difference between its performance and human
physiology core laboratories. The foundational trials
FIGURE 4 Repeatability Between Pairs
Each panel displays paired measurements at the smart minimum FFR as depicted in the right panel of Figure 1: FFR (upper left),
Pd (upper right), Pa (lower right), and heart rate (HR) (lower left panel). As quantiﬁed by various statistical measures (Pearson [r] and
intraclass correlation coefﬁcient [ICC]), FFR demonstrates the highest repeatability. Abbreviations as in Figure 1.
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1024supporting FFR (2–4) did not use centralized physi-
ology core laboratories, meaning their results gener-
alize to cardiologists in daily practice. Instead, this
algorithm has the potential to improve the quality of
FFR information, thereby reducing unwanted vari-
ability and uncertainty in clinical decision making.
Because FFR has become a standard measure of
physiological stenosis severity, understanding the
mechanisms behind our observations carries clinical
and physiological relevance. The VERIFY study was
not designed to address this separate question. Sub-
sequent studies could measure pressure and ﬂow
together, titrate the adenosine infusion dose,
compare patterns of response among various hyper-
emic drugs, measure serum caffeine levels, andadd alpha- and beta-receptor modulators (agonists
and antagonists) to distinguish among potential
mechanisms. Although we await these future mech-
anistic insights, our present results have demon-
strated that the minimum FFR value remains robustly
repeatable for clinical application.
COMPARISON TO EXISTING PUBLISHED DATA.
Almost 25 years ago, IV adenosine infusion for hy-
peremia was introduced by comparison to papaverine
and was evaluated using an intracoronary 3-F Doppler
catheter (9). Those authors also observed ﬂow varia-
tions consistent with the “humped” response in our
Figure 2: “At the lower infusion rates.coronary blood
ﬂow velocity often rose and fell in a cyclic pattern
FIGURE 6 Distribution of Times to FFR
A cumulative distribution of times from the start of the ﬁrst recording until the smart
minimum FFR demonstrates that 50% of cases occur within 74 s, whereas only 16% occur
after 2 min. Intravenous adenosine at 140 mg/kg/min began approximately 10 cardiac
cycles into the recording. Three example Pd/Pa tracings depict progressive differences in
the waiting period for FFR during a steady intravenous adenosine infusion. Abbreviations
as in Figure 1.
FIGURE 5 Repeatability of FFR Despite Variability of Hyperemia
(Left) Bland-Altman analysis of repeated smart FFR measurements demonstrates no signiﬁcant bias (D ¼ 0.001, paired p ¼ 0.93) with an SD
of approximately 0.02. However, the variability of Pd/Pa during the hyperemic period (right) reveals a wide range. Three example tracings
depict progressive differences in the stability of Pd/Pa during the hyperemic period, marked in each tracing as a blue box with height 0.02
(roughly the SD for repeated FFR measurements). For each example, the red dot locates the smart minimum FFR and the colored green area
denotes the portion of the hyperemic period outside of the stable blue box. Abbreviations as in Figure 1.
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1025with a cycle length of about 30 seconds.when the
coronary infusion rate was increased, hyperemia
became sustained at the maximal level.” Indeed, the
case shown in their Figure 5 displays a “humped”
response in ﬂow levels, albeit at lower IV infusion
rates than in our VERIFY reanalysis, but with similar
periodicity. Their Table 4 describes “cyclic variation”
in 3 of 30 arteries (10%) even at a rate of 140 mg/kg/min,
compared to 39% in our Figure 2.
Because they focused on ﬂow changes and FFR had
not yet been introduced, their data only indirectly
supports a common mechanism between their
Doppler ﬂow velocity cycles and the humps in our
Pd/Pa tracings. However, their ﬁnding that these cy-
cles diminished at higher rates of IV adenosine infu-
sion suggests that future work could determine
whether the incidence of Pd/Pa “humps” falls at rates
of 180 or 210 mg/kg/min or with direct right atrial or
intracoronary infusion. We found signiﬁcant variation
in Pd/Pa patterns among coronary vessels. Although
the adenosine dose is weight-adjusted for the entire
subject, it might be necessary to adjust the dose for the
unmeasurable distalmyocardialmass to achieve stable
receptor saturation. The shorter duration until the
transition to hyperemia observed during the repeat
measurement (43 s vs. 35 s), and the larger conversion
from humped then classic compared to classic then
humped (37 pairs vs. 21 pairs, respectively) both
PERSPECTIVES
WHAT IS KNOWN? FFR improves clinical outcomes
and requires hyperemia, often achieved with an IV
adenosine infusion. However, uncertainly exists
regarding FFR repeatability and stability during IV
adenosine infusion because of systemic effects that
can alter driving pressure and heart rate.
WHAT IS NEW? Although various patterns of
coronary pressure and systemic hemodynamic
response exist during IV adenosine infusion, the
minimum FFR value remains highly repeatable and its
selection can be successfully automated.
WHAT IS NEXT? Future studies could explore the
mechanisms behind response patterns during IV
adenosine infusion and determine if similar effects
exist with other systemic vasodilators like
regadenoson.
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1026suggest residual effects or a “priming” from IV aden-
osine even after a 2-min rest period.
Recent work proposed 7 patterns of response to IV
adenosine infusion, but with an emphasis on Pa and Pd
separately and without repeated, paired tracings for
the same lesion (11). However, as clariﬁed in our
Figure 4, Pa and Pd responses vary markedly even for
the same patient when repeating an FFR measure-
ment. Rather, only the Pd/Pa ratio displays a highly
repeatable response. Furthermore, as summarized in
our Figure 2, approximately 40% of tracings do not
reach a stable state, thereby invalidating their pro-
posed 3 classiﬁcation stages of “base,” “peak,” and
“stable.” In contradistinction to their recommenda-
tion that “ideally, measurements should only be made
when stable hyperemia is achieved after $60 s of
stable intravenous adenosine infusion” (11), our
Table 1 demonstrates that waiting 1 or even 2 min in
hopes of achieving a “stable” period performs worse
than always selecting the “smart minimum” FFR.
Indeed, our results in Figure 6make it unlikely that any
“1 size ﬁts all” solution exists for timing.
Other recent work proposed 3 patterns of response
to IV adenosine infusion, but again with an emphasis
on Pa and Pd separately and without repeated,
paired tracings for the same lesion (12). Although
noting similar remarks as we previously mentioned
regarding paired measurements and highly repeatable
“smart minimum” FFR values, we do agree with these
authors that FFR pullback curves could be affected by
the “humped” response pattern that occurs in roughly
40% of cases. We suggest 3 solutions: rapid pullback
during the nadir phase, increased IV adenosine rate
that might convert to a “classic” pattern, or serial sta-
tionary measurements along the artery of sufﬁcient
duration to obtain a “smart minimum” FFR.
STUDY LIMITATIONS. The VERIFY study only recor-
ded intracoronary pressure. Measuring pressure and
ﬂow simultaneously might allow distinction between
mechanisms responsible for the observed “humps” in
Pd/Pa tracings. Geometric changes in stenosis geom-
etry due to ﬂow-mediated vasodilation should change
the pressure loss versus ﬂow relationship, whereas
oscillations in microvascular resistance due to
incomplete adenosine saturation should follow the
same quadratic curve. Future work could repeat the
VERIFY design but measure both pressure and ﬂow.
Our study used test/retest repeatability and
agreement with human physiology core laboratories
as its benchmarks. We, therefore, cannot comment on
its effect on clinical events, although repeatability is
generally considered an advantage in patient man-
agement guided by threshold criteria.CONCLUSIONS
Our results can be summarized simply for clinical
application: within reason, always take the minimum
FFR value. Although the Pd/Pa curve will not always
reach a stable shelf, and various patterns of response
exist to IV adenosine infusion, the minimum FFR
value remains a highly repeatable measurement. In
the future, automatic software will likely be able to
select the correct FFR value with similar performance
to a human physiology core laboratory. Sparkline
displays of Pd/Pa provide a concise visualization of
intracoronary pressure data.
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